FDA
-
-
-
-
-
-
-
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Relay Therapeutics (RLAY)
-
-
-
-
-
-
-
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
-
-
-
-
-
-
-
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
-
-
-
-
-
-
-
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/12: (RRD) (TARA) (QTRX) Higher; (CVAC) (RLAY) (TREX) Lower (more...)
-
-
-
-
-
-
-
Relay Therapeutics Reports Second Quarter 2020 Financial Results
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

